---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-153420"
form_type: "8-K"
ticker: "ANNX"
cik: "0001528115"
company_name: "Annexon, Inc."
filed_at: "2023-05-25T23:59:59+00:00"
generated_at: "2026-06-14T14:28:42.352414+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Annexon ARCHER Ph2: ANX007 shows stat-sig vision loss protection, primary lesion growth endpoint missed

## Summary
- ANX007 monthly reduced risk of ≥15-letter BCVA loss by 72% (p=0.006); pooled 59% (p=0.008).
- Primary endpoint GA lesion growth rate reduction not met: monthly 6.2% (p=0.526), EOM 1.3% (p=0.896).
- ANX007 well-tolerated; 3 SAEs endophthalmitis (injection-related), 3 SAEs intraocular inflammation suspected treatment-related.
- First complement therapy to show preservation of visual function in a prospective 12-month GA trial.
- Company plans regulatory engagement for optimal path forward; webcast today 1:30pm PT.

## SEC filing metadata
- accession: 0001193125-23-153420
- form_type: 8-K
- ticker: ANNX
- cik: 0001528115
- company_name: Annexon, Inc.
- filed_at: 2023-05-25T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1528115/000119312523153420/0001193125-23-153420-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1528115/000119312523153420/d468662d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-153420
- JSON: https://secwatch.observer/filing/0001193125-23-153420.json
- Plain text: https://secwatch.observer/filing/0001193125-23-153420.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.